neutropenia
import
particularli
sever
polymorphonuclear
neutrophil
prolong
day
risk
factor
includ
mucos
underli
diseas
statu
intens
chemotherapi
use
biolog
respons
modifi
especi
monoclon
antibodi
alemtuzumab
rituximab
presenc
central
venou
cathet
genet
factor
epidemiolog
bloodstream
infect
neutropenia
constantli
chang
year
predomin
gramposit
cocci
gramneg
rod
emerg
mani
center
frequent
pathogen
shift
accompani
increas
rate
resist
pathogen
extendedspectrum
enterobacteriacea
carbapenemresist
gramneg
pathogen
methicillinresist
staphylococcu
aureu
methicillinresist
staphylococcu
epidermidi
vancomycinresist
enterococci
main
challeng
manag
multidrugresist
mdr
gramneg
bacteria
therapeut
option
exist
invas
fungal
diseas
ifd
hematolog
patient
caus
mainli
aspergillu
turn
caus
widespread
use
candidaact
fluconazol
prophylaxi
emerg
fluconazoleresist
strain
natur
consequ
wherea
solidorgan
tumor
candidemia
remain
frequent
ifd
prophylaxi
see
tabl
gener
antibacteri
antifung
antivir
prophylaxi
indic
patient
receiv
induct
chemotherapi
acut
myelogen
leukemia
aml
influenza
varicella
vaccin
household
contact
health
care
worker
recommend
influenza
pneumococc
vaccin
patient
especi
less
aggress
treatment
phase
recommend
fluoroquinolon
recommend
patient
prolong
day
neutropenia
center
resist
fluoroquinolon
less
primari
antifung
prophylaxi
cancer
patient
usual
recommend
incid
ifd
higher
fluconazol
recommend
yeastact
prophylaxi
aml
patient
receiv
anthracyclin
regimen
posaconazol
moldact
prophylaxi
recommend
patient
receiv
chemotherapi
aml
myelodysplast
syndrom
secondari
antifung
prophylaxi
administ
patient
previou
ifd
receiv
highintens
chemotherapi
transplant
prophylaxi
pneumocysti
jirovecii
usual
trimethoprimsulfamethoxazol
three
time
per
week
benefici
patient
deficit
tcellular
immun
particularli
chronic
lymphocyt
leukemia
receiv
highdos
corticosteroid
alemtuzumab
antiherp
prophylaxi
acyclovir
valacyclovir
offer
patient
acut
leukemia
receiv
alemtuzumab
varicella
postexposur
prophylaxi
specif
immunoglobulin
acyclovir
recommend
highrisk
varicellazost
virussuscept
patient
antipseudomona
monotherapi
deescal
strategi
start
combin
antipseudomona
plu
agent
cover
probabl
resist
pathogen
agent
discontinu
resist
pathogen
isol
empir
antifung
therapi
ad
antifung
agent
patient
persist
febril
despit
broadspectrum
antibiot
could
replac
diagnosticdriven
strategi
base
use
diagnost
tool
chest
comput
tomographi
scan
fungal
serum
marker
galactomannan
era
increas
antibiot
resist
agent
activ
mdr
pathogen
antimicrobi
stewardship
cancer
center
mandatori
includ
infectioncontrol
practic
local
surveil
antibiot
resist
antibiot
consumpt
patient
outcom
promot
appropri
antibiot
use
time
deescal
appropri
dose
establish
antibiot
regiment
empir
therapi
appropri
local
epidemiolog
crucial
question
type
stage
underli
diseas
clinic
present
make
thought
effect
intervent
among
other
factor
potenti
associ
presenc
highli
resist
bacteri
strain
current
care
consid
infect
cancer
patient
often
consid
nosocomi
despit
fact
patient
often
care
outpati
even
homecar
basi
fact
studi
infecti
complic
adult
receiv
treatment
acut
hematolog
malign
show
infecti
episod
actual
associ
type
care
patient
receiv
episod
truli
nosocomi
origin
reason
terminolog
health
careassoci
infect
appropri
describ
infect
cancer
manag
field
case
even
develop
hospit
infect
cancer
patient
necessarili
consid
result
bad
clinic
practic
rate
necessarili
decreas
except
infect
control
measur
infecti
pathogen
come
endogen
sourc
follow
section
epidemiolog
manag
principl
infect
cancer
patient
describ
risk
factor
clinic
present
specif
infect
along
treatment
nonneutropen
cancer
patietn
discuss
dealt
chapter
focus
individu
infecti
agent
similarli
infect
recipi
allogen
hematopoiet
stem
cell
transplant
hsct
discuss
elsewher
see
chapter
touch
patient
especi
correl
earli
infect
preengraft
neutropen
phase
absenc
neutropenia
final
new
peculiar
aspect
emerg
use
biolog
respons
modifi
becom
part
mani
chemotherapeut
regimen
pose
new
challeng
consid
howev
compar
previou
edit
principl
practic
infecti
diseas
import
chang
updat
version
chapter
repres
phenomenon
grow
antibiot
bacteri
resist
worldwid
also
obvious
impact
manag
infect
cancer
patient
antibioticresist
pathogen
enterobacteriacea
resist
thirdgener
cephalosporin
produc
extendedspectrum
esbl
carbapenem
multidrugresist
mdr
pseudomona
aeruginosa
methicillinresist
staphylococcu
aureu
mrsa
methicillinresist
staphylococcu
epidermidi
mrse
vancomycinintermedi
staphylococcu
aureu
visa
vancomycinresist
enterococci
vre
initi
confin
intens
care
unit
icu
spread
ward
mani
countri
northsoutheastwest
gradient
endem
sporad
case
singl
ward
affect
everywher
world
radic
chang
abil
prevent
cure
infect
immunocompromis
new
antibiot
horizon
challeng
ensur
increas
antimicrobi
resist
revers
gain
made
improv
surviv
outcom
patient
cancer
target
therapi
better
surgic
techniqu
shown
tabl
clinic
approach
cancer
patient
sign
symptom
infect
multifactori
plan
ration
manag
intervent
physician
answer
sever
possibl
lack
absorpt
pkpd
problem
breakthrough
infect
possibl
fever
prophylaxi
consid
failur
prophylaxi
unless
proven
otherwis
occurr
bacterialfungalvir
infect
specif
prophylaxi
may
influenc
choic
empir
therapi
depend
drug
use
prophylaxi
resist
pathogen
suspect
everi
case
unless
patient
clearli
noncompli
andor
possibl
low
drug
level
caus
poor
absorpt
increas
metabol
drug
interact
eg
azol
itraconazol
voriconazol
posaconazol
knowledg
local
epidemiolog
includ
suscept
pattern
mandatori
correct
diagnost
therapeut
manag
hsct
hematopoiet
stem
cell
transplant
pkpd
pharmacokineticpharmacodynam
pmn
polymorphonuclear
neutrophil
lymphoblast
leukemia
chronic
lymphat
disord
multipl
myeloma
nonhodgkin
lymphoma
wherea
lowest
rate
observ
solid
tumor
although
may
larg
depend
antineoplast
treatment
strategi
patient
chronic
leukemia
multipl
myeloma
may
repres
peculiar
group
role
play
use
new
biolog
respons
modifi
imatinib
desatinib
rituximab
alemtuzumab
etc
new
drug
potenti
modifi
risk
profil
infecti
complic
increas
risk
infect
also
caus
previous
unusu
pathogen
pneumocysti
jirovecii
variou
virus
neutropenia
although
first
scientist
show
pivot
studi
direct
relationship
infect
neutropenia
gerald
bodey
houston
first
report
risk
report
term
infect
rate
probabl
publish
carlisl
colleagu
show
rate
infect
neutropen
cancer
patient
episod
per
day
neutropenia
dn
rate
bacteremia
invas
mycos
recent
data
prospect
studi
children
adult
neutropenia
show
median
incid
infecti
complic
rate
episod
per
dn
bacteremia
diagnos
episod
mold
infect
rate
dn
respect
shown
tabl
rate
infect
higher
highintens
chemotherapi
lower
mainten
treatment
although
epidemiolog
infect
studi
extens
children
gener
data
adult
report
higher
rate
infecti
complic
compar
pediatr
popul
major
primari
febril
episod
usual
occur
soon
day
onset
neutropenia
alreadi
mention
addit
neutropenia
sever
mucos
barrier
injuri
may
impact
infect
rate
inde
demonstr
patient
receiv
hsct
fever
knowledg
incid
fever
document
infect
cancer
patient
accord
type
underli
diseas
relat
chemotherapi
mandatori
implement
effect
manag
strategi
especi
prophylaxi
howev
larg
major
epidemiolog
data
patient
come
studi
empir
antibiot
therapi
prophylaxi
patient
select
accord
inclus
exclus
criteria
thu
approach
might
inadequ
describ
actual
epidemiolog
situat
real
life
addit
littl
inform
avail
nonneutropen
patient
epidemiolog
data
incid
infect
usual
report
percentag
event
given
number
patient
treatment
cours
without
adjust
durat
period
risk
probabl
wrong
durat
exposur
crucial
understand
clinic
impact
given
phenomenon
probabl
appropri
speak
incid
rate
number
event
given
risk
period
usual
day
tabl
report
epidemiolog
febril
episod
bacteremia
invas
mycos
cancer
patient
data
clearli
show
incid
rate
proport
infecti
complic
mainli
relat
intens
antineoplast
chemotherapi
addit
factor
repres
phase
chemotherapi
statu
neoplast
diseas
higher
incid
infecti
complic
patient
receiv
remissioninduct
rescu
chemotherapi
compar
mainten
consolid
firstlin
treatment
state
underli
diseas
term
remiss
relaps
progress
also
import
factor
occurr
prognosi
infecti
complic
shown
studi
patient
invas
aspergillosi
patient
acut
myeloid
leukemia
adult
children
highest
frequenc
fever
bacteremia
invas
fungal
diseas
especi
first
induct
remiss
relaps
leukemia
intens
chemotherapi
higher
lower
frequenc
observ
strictli
relat
sever
mucos
barrier
injuri
independ
sever
durat
myelosuppress
mucos
one
import
factor
predispos
bloodstream
infect
caus
bacteria
candida
damag
mucos
barrier
allow
colon
pathogen
enter
bloodstream
absenc
granulocyt
sever
infect
rapidli
develop
even
case
low
bacteri
load
mucos
without
neutropenia
might
also
respons
sever
oral
intestin
infect
pathogenesi
role
mucos
chemotherapi
describ
detail
elsewher
see
chapter
presenc
central
venou
cathet
cvc
anoth
wellknown
factor
facilit
infect
cancer
patient
influenc
etiolog
bacteremia
tabl
report
incid
cvcrelat
complic
cancer
patient
bacteremia
repres
frequent
condit
wherea
exit
site
tunnel
type
cvcrelat
infect
less
frequent
report
complic
frequent
partial
implant
total
implant
cathet
also
doublelumen
compar
singlelumen
devic
noteworthi
patient
total
implant
cvc
infecti
complic
frequent
younger
patient
hematolog
malign
categori
number
cvc
manipul
mainli
relat
intens
antineoplast
chemotherapi
sever
clinic
condit
repres
import
risk
factor
develop
infect
detail
descript
complex
problem
cvcrelat
infect
beyond
scope
chapter
found
elsewher
see
chapter
incid
cvcrelat
infect
kept
minimum
sever
educ
organiz
measur
repeat
teach
session
patient
parent
staff
establish
team
dedic
insert
mainten
intravascular
devic
technic
measur
suggest
includ
use
chlorhexidineimpregn
dress
spong
antisepticantimicrobi
coat
intravascular
cathet
exampl
chlorhexidin
silver
sulfadiazin
benefit
routin
use
depend
cost
observ
rate
outcom
cvc
infect
case
antibioticimpregn
devic
risk
induc
antimicrobi
resist
exist
genet
factor
abl
increas
decreas
suscept
infect
immunocompromis
patient
underlin
appar
trivial
import
aspect
cancer
patient
everi
singl
patient
might
deserv
individu
approach
exampl
nonleukem
patient
receiv
less
intens
chemotherapi
decreas
level
mannosebind
protein
associ
increas
risk
infect
vs
day
risk
p
effect
less
evid
context
prolong
neutropenia
confirm
studi
howev
recent
studi
children
cancer
mannosebind
lectin
defici
influenc
incid
sever
febril
neutropenia
polymorph
tolllik
receptor
compon
innat
immun
associ
increas
risk
invas
aspergillosi
cancer
patient
includ
recipi
hsct
immunocompromis
patient
futur
tell
us
whether
genet
polymorph
alon
combin
actual
impact
might
dictat
prophylact
therapeut
approach
alreadi
mention
recent
year
monoclon
antibodi
pharmaceut
compound
specif
engin
target
cell
cytokin
involv
pathogenesi
specif
diseas
introduc
armamentarium
antineoplast
chemotherapi
includ
biolog
respons
modifi
protein
kinas
inhibitor
alemtuzumab
monoclon
antibodi
receptor
use
treatment
acut
chronic
lymphocyt
leukemia
nonhodgkin
lymphoma
monoclon
antibodi
clear
role
increas
infect
risk
associ
longlast
profound
lymphopenia
bacteremia
invas
fungal
diseas
includ
pneumocystosi
sever
viral
diseas
tuberculosi
describ
associ
drug
low
tlymphocyt
count
possibl
cutoff
mm
indic
one
import
factor
relat
develop
infecti
complic
obvious
infect
seem
common
sever
clinic
pictur
patient
previous
treat
antineoplast
protocol
rituximab
bcell
antibodi
caus
prolong
month
median
sometim
suppress
immunoglobulin
product
associ
reactiv
acut
exacerb
viral
hepat
hepat
b
viru
hbv
c
viru
hcv
rare
dissemin
parvoviru
infect
enterovir
mening
progress
multifoc
leukoencephalopathi
babesiosi
pneumocystosi
bacteri
fungal
diseas
also
describ
usual
rituximab
administ
combin
chemotherapeut
agent
monoclon
antibodi
ibritumomab
tositumomab
ofatumumab
ocrelizumab
less
data
infecti
complic
exist
monoclon
antibodi
report
caus
sever
myelosuppress
spectrum
infecti
complic
somewhat
similar
associ
classic
cytostat
drug
noteworthi
patient
receiv
antilymphocyt
monoclon
antibodi
andor
relaps
diseas
ie
previou
prolong
chemotherapi
cycl
present
frequent
sever
complic
appar
lower
surgeri
nonmalign
condit
hepatolithiasi
rate
infecti
complic
hepatectomi
hepatocarcinoma
associ
surgic
risk
factor
bile
leakag
blood
loss
similar
incid
surgic
site
infect
report
elect
colon
rectal
surgeri
respect
orthoped
surgeri
interest
latter
studi
use
implant
allograft
repres
risk
factor
infecti
complic
final
postop
respiratori
infect
report
nearli
patient
undergo
surgeri
lung
cancer
occur
frequent
presenc
advanc
age
impair
respiratori
function
advanc
patholog
stage
induct
chemotherapi
conclus
although
mani
data
avail
infecti
complic
surgeri
solid
tumor
seem
surgic
icurel
factor
import
previou
antineoplast
chemotherapi
determin
risk
infect
howev
must
note
patient
solid
tumor
surgeri
togeth
long
hospit
stay
use
thirdgener
cephalosporin
glycopeptid
associ
increas
risk
infect
caus
mdr
pathogen
etiolog
surveil
studi
pathogen
caus
infect
cancer
patient
utmost
import
implement
manag
strategi
largescal
studi
obvious
crucial
provid
inform
worldwid
trend
singlecent
surveil
report
import
everi
center
may
peculiar
relat
type
patient
type
care
local
histor
antibiot
polici
avail
inform
concern
bacteri
fungal
pathogen
isol
bloodstream
wherea
role
deepseat
infect
less
known
well
impact
viral
infect
last
year
gramposit
bacteria
frequent
pathogen
bloodstream
infect
cancer
patient
howev
recent
increas
frequenc
bacteremia
caus
gramneg
rod
report
mani
center
worldwid
gramneg
pathogen
becom
either
predomin
least
frequent
gramposit
pathogen
trend
observ
also
result
recent
literatur
review
european
surveil
studi
perform
hematolog
center
countri
fourth
european
confer
infect
leukemia
shown
figur
gramneg
pathogen
almost
frequent
gramposit
one
gramposit
versu
gramneg
ratio
bloodstream
infect
versu
versu
literatur
review
surveil
respect
detail
etiolog
similar
see
fig
literatur
review
surveil
studi
slightli
increas
rate
enterococci
enterobacteriacea
decreas
rate
p
aeruginosa
surveil
studi
chang
etiolog
seem
accompani
import
alarm
increas
proport
resist
pathogen
esblproduc
enterobacteriacea
vre
worrisom
carbapenemresist
gramneg
pathogen
p
aeruginosa
enterobacteriaceaemostli
klebsiella
pneumonia
last
least
leukemia
patient
staphylococci
resist
methicillin
wherea
gramneg
pathogen
fluoroquinolon
resist
note
rate
resist
gener
higher
southern
eastern
europ
northern
western
europ
anaerob
bacteria
isol
less
posit
blood
cultur
cancer
patient
proport
may
increas
among
undergo
abdomin
surgeri
anaerob
usual
isol
polymicrobi
bacteremia
especi
togeth
gramneg
rod
rate
seem
higher
observ
nononcolog
patient
undergo
similar
surgeri
vs
hospit
day
respect
interest
nonneutropen
febril
cancer
patient
gramneg
pathogen
frequent
isol
follow
gramposit
pathogen
yeast
filament
fungi
probabl
relat
sever
gastrointestin
mucos
cvcrelat
bacteremia
gener
caus
gramposit
compar
receiv
frontlin
therapi
bevacizumab
anoth
monoclon
antibodi
target
vascular
endotheli
growth
factor
use
colon
kidney
brain
lung
cancer
febril
neutropenia
bacteri
infect
report
approxim
patient
usual
drug
use
combin
chemotherapeut
agent
cetuximab
approv
colon
head
neck
cancer
panitumumab
approv
colon
cancer
epiderm
growth
factor
receptor
main
target
activ
caus
import
dermatolog
toxic
rash
skin
dri
fissur
paronychi
inflamm
infecti
complic
patient
includ
sepsi
caus
aureu
trastuzumab
react
human
epiderm
growth
factor
receptor
administ
usual
combin
standard
chemotherapi
treatment
breast
gastric
cancer
infect
associ
compound
gener
mild
though
infrequ
may
exacerb
chemotherapyinduc
neutropenia
small
molecul
protein
kinas
activ
target
oncogen
tyrosin
kinas
bcrabl
breakpoint
cluster
regionabelson
murin
leukemia
imatinib
desatinib
nilotinib
use
patient
acut
chronic
leukemia
solid
tumor
even
long
period
time
infecti
complic
seem
similar
observ
immunosuppress
drug
affect
mechan
cellmedi
immun
pneumocystosi
viral
diseas
includ
reactiv
hepat
absenc
major
myelosuppress
appar
increas
rate
bacteri
fungal
infect
final
kinas
inhibitor
sunitinib
sorafenib
use
nephrectomi
renal
cell
carcinoma
hepatocellular
carcinoma
drug
appar
increas
risk
surgic
infect
although
one
sunitinib
associ
necrot
fasciiti
respiratori
infect
sepsi
sever
problem
impair
abil
understand
exact
role
new
compound
risk
infect
cancer
patient
even
random
placebocontrol
trial
larg
openlabel
studi
difficult
establish
rate
infecti
complic
main
reason
trial
power
measur
efficaci
safeti
effect
rare
might
go
undetect
second
mani
confound
factor
new
drug
usual
use
togeth
old
classic
therapi
make
difficult
imposs
evalu
respect
role
addit
trial
use
definit
infecti
complic
simpli
pay
enough
attent
diagnos
sadli
case
tendenc
toward
minim
cover
final
case
enough
attent
forecast
risk
infect
case
eculizumab
use
paroxysm
nocturn
hemoglobinuria
target
complement
compon
wide
known
among
infecti
diseas
physician
deal
infect
immunocompromis
host
inherit
defici
complement
compon
associ
repeat
episod
meningococc
diseas
thu
risk
might
forecast
bacteremia
usual
associ
surgic
site
infect
deep
organ
abscess
uncommon
urolog
gynecolog
abdomin
surgeri
cancer
patient
difficult
say
certainti
happen
significantli
often
among
oncolog
versu
nononcolog
patient
sever
studi
report
rate
postsurgeri
infect
differ
cancer
popul
exampl
among
patient
periton
carcinomatosi
undergo
peritonectomi
intraperiton
hypertherm
chemotherapi
proport
infecti
complic
rather
high
vari
two
infecti
episod
per
patient
rate
infecti
complic
lower
oncolog
surgeri
breast
cancer
surgic
site
infect
complic
case
depend
whether
breast
reconstruct
perform
one
two
step
whether
surgeri
follow
previou
chemotherapi
cycl
case
malign
biliari
obstruct
earli
infecti
complic
percutan
biliari
stent
insert
present
patient
similar
incid
report
patient
undergo
surgeri
hepatocellular
metastat
carcinoma
incid
probabl
underestim
underdiagnos
cancer
popul
although
data
show
rate
approxim
case
per
person
ie
ninefold
higher
gener
popul
develop
countri
patient
highendem
countri
belong
racial
ethnic
minor
account
case
contrari
infect
caus
nontubercular
mycobacteria
rare
note
dissemin
tuberculosi
caus
mycobacterium
bovi
may
occur
patient
receiv
bacillu
immunotherapi
bladder
cancer
etiolog
fungal
infect
cancer
patient
shown
tabl
aspergillu
spp
candida
spp
common
fungal
pathogen
former
seen
frequent
latter
fungal
pathogen
includ
p
jirovecii
cryptococci
mold
mucoral
fusarium
among
yeast
candida
frequent
isol
organ
usual
bloodstream
infect
increas
proport
nonalbican
strain
least
partli
correl
extens
use
prophylact
fluconazol
nonalbican
strain
resist
less
suscept
alreadi
european
organis
research
treatment
cancer
eortc
studi
c
albican
respons
candidemia
patient
hematolog
malign
episod
solid
tumor
cocci
especi
coagulaseneg
staphylococci
isol
episod
compar
rate
gramneg
rod
sourc
infect
like
partial
differ
gramposit
neg
cvcrelat
bacteremia
case
contamin
skin
hub
caus
incorrect
cathet
manag
pivot
although
mani
gramposit
cocci
come
directli
patient
skin
flora
infus
contamin
rare
possibl
event
case
gramneg
rod
klebsiella
enterobact
citrobact
achromobact
serratia
pseudomona
p
aeruginosa
like
involv
polymicrobi
infect
rare
episod
predomin
gramneg
bacteria
wherea
fungi
mainli
candida
spp
usual
isol
cvcrelat
bloodstream
infect
bacteri
gastroenter
caus
classic
enter
pathogen
salmonella
shigella
rare
event
patient
acut
leukemia
involv
less
acut
enter
chemotherapi
contrari
clostridium
difficil
unusu
cancer
patient
incid
twofold
higher
noncanc
popul
helicobact
pylori
also
describ
possibl
caus
gastrointestin
gi
diseas
cancer
patient
mycoplasma
pneumonia
chlamydia
pneumonia
rare
describ
caus
pneumonia
cancer
patient
possibl
incid
underreport
similarli
tuberculosi
coagulaseneg
staphylococci
viridan
streptococci
enterococci
gram
posit
enterobacteriacea
gram
neg
gram
posit
enterobacteriacea
p
aeruginosa
acinetobact
gram
neg
upper
respiratori
ill
sever
immun
deficit
treat
leukemia
increas
risk
progress
upper
respiratori
tract
infect
pneumonia
possibl
respiratori
failur
fatal
outcom
incid
rate
viral
respiratori
infect
patient
acut
lymphocyt
acut
myelogen
leukemia
estim
infect
per
new
admiss
respect
almost
half
patient
pneu
monia
mortal
cancer
patient
viral
respiratori
diseas
deferr
chemotherapi
could
consid
specif
treatment
warrant
influenza
case
rsv
infect
eg
leukem
patient
risk
factor
rsvrelat
mortal
viral
gastroenter
mainli
caus
rotaviru
also
noroviru
sapoviru
may
frequent
complic
pediatr
oncolog
potenti
caus
outbreak
cancer
center
persist
gi
shed
immunocompromis
host
adenovirus
parvoviru
report
rare
caus
sever
gastrointestin
diseas
cancer
patient
final
reactiv
hepatotrop
virus
hbv
hcv
repres
import
problem
area
high
endem
hbv
reactiv
infrequ
cancer
patient
chronic
inact
hbv
infect
hepat
b
surfac
antigen
hbsag
posit
neg
lowlevel
serum
hbv
dna
occur
also
patient
occult
hbv
infect
hbsag
neg
hepat
b
core
antibodi
hbcab
posit
lowlevel
serum
hbv
dna
particularli
associ
use
rituximab
risk
unusu
infect
reactiv
caus
protozoa
leishmaniasi
south
american
trypanosomiasi
malaria
helminth
strongyloidiasi
tropic
diseas
consid
patient
live
endem
area
obtain
histori
identifi
potenti
exposur
import
screen
tool
exampl
strongyloidiasi
suboptim
perform
stool
examin
serolog
screen
warrant
empir
treatment
patient
present
unexplain
eosinophilia
live
endem
area
tropic
subtrop
southeastern
unit
state
europ
prevent
obvious
desir
goal
given
remark
mortal
morbid
associ
infect
cancer
patient
tabl
summar
differ
regimen
primari
chemoprophylaxi
approach
consid
appropri
cancer
patient
base
clinic
trial
guidelin
follow
section
advantag
disadvantag
differ
procedur
discuss
use
antibiot
prevent
bacteri
infect
weigh
efficaci
toxic
impact
develop
resist
gener
evalu
costeffect
prophylact
protocol
one
know
everi
center
rate
complic
prevent
consequ
number
patient
need
treat
prevent
occurr
singl
infecti
episod
attribut
death
chemoprophylaxi
prevent
bacteri
infect
first
propos
clinic
practic
base
discoveri
bacteri
pathogen
caus
infect
neutropen
cancer
patient
origin
patient
endogen
flora
approxim
half
infect
acquir
hospit
stay
first
approach
reli
administr
nonabsorb
antibiot
aim
total
includ
anaerob
partial
exclud
anaerob
suppress
intestin
bacteri
flora
prevent
acquisit
exogen
organ
oral
gentamicin
vancomycin
nystatin
use
subsequ
absorb
drugsfirst
trimethoprimsulfamethoxazol
tmpsmx
usual
given
combin
oral
nystatin
amphotericin
band
fluoroquinolon
introduc
metaanalysi
publish
show
prophylaxi
neutropenia
absorb
drug
especi
quinolon
significantli
reduc
risk
death
rate
similarli
recent
eortc
data
patient
fungemia
present
european
congress
clinic
microbiolog
infecti
diseas
report
overal
incid
c
albican
respons
monomicrobi
infect
note
fungemia
occur
neutropenia
gener
yeast
belong
candida
parapsilosi
complex
usual
associ
cvc
contamin
wherea
candida
speci
suppos
come
gi
tract
select
transloc
among
mold
aspergillu
repres
frequent
isol
suspect
organ
major
episod
caus
aspergillu
fumigatu
although
center
report
predomin
infect
caus
aspergillu
flavu
aspergillu
terreu
aspergillu
speci
ubiquit
mold
whose
primari
ecolog
nich
repres
decompos
veget
materi
includ
pot
plant
soil
flower
carpet
healthi
individu
aspergillu
conidia
trap
upper
respiratori
tract
small
proport
enter
lower
airway
aspergillu
may
becom
allergen
immunocompromis
patient
especi
hematolog
malign
allogen
transplant
spore
germin
caus
invas
diseas
thu
invas
aspergillosi
patient
malign
receiv
hsct
endem
diseas
usual
commun
acquir
endogen
although
epidem
outbreak
exogen
infect
associ
massiv
environment
exposur
outsid
hospit
occur
incid
invas
aspergillosi
depend
patient
age
lower
younger
year
underli
malign
treatment
highest
patient
prolong
neutropenia
follow
receiv
high
dose
steroid
therapi
multicent
italian
studi
incid
aspergillosi
among
hematolog
patient
vari
acut
nonlymphoblast
leukemia
acut
lymphoblast
leukemia
chronic
myelogen
leukemia
less
chronic
lymphocyt
leukemia
hodgkin
diseas
nonhodgkin
lymphoma
multipl
myeloma
recent
describ
risk
group
repres
patient
chronic
lymphoprolif
disord
probabl
result
intens
treatment
protocol
incid
invas
aspergillosi
autolog
hsct
low
occur
neutropenia
preced
engraft
p
jirovecii
wellknown
caus
pneumonia
cancer
patient
receiv
specif
prophylaxi
especi
associ
highdos
prolong
steroid
therapi
attack
rate
vari
acut
lymphoblast
leukemia
rhabdomyosarcoma
nearli
hodgkin
diseas
primari
metastat
central
nervou
system
tumor
center
increas
report
mucormycosi
howev
unclear
whether
repres
gener
trend
influenc
local
factor
infect
simpli
diagnos
often
increas
clinic
awar
fungi
cryptococcu
fusarium
blastoschizomyc
trichosporon
scedosporium
report
sporad
final
infect
reactiv
dimorph
fungi
histoplasma
coccidioid
possibl
patient
live
use
live
endem
area
apart
herp
simplex
viru
hsv
reactiv
occur
hsvseroposit
patient
acut
leukemia
viral
infect
rather
infrequ
report
outsid
set
allogen
hsct
exampl
posit
antigenemia
cytomegaloviru
cmv
report
nonhsct
recipi
patient
undergo
autolog
hsct
without
necessarili
accompani
cmv
diseas
reason
routin
monitor
cmv
reactiv
preemptiv
therapi
consid
necessari
cancer
patient
hsct
recipi
howev
risk
viral
reactiv
might
chang
significantli
increas
use
novel
tcellsuppress
agent
particularli
alemtuzumab
communityacquir
respiratori
virus
respiratori
syncyti
viru
rsv
influenza
parainfluenza
virus
adenovirus
rhinovirus
coronavirus
frequent
caus
respiratori
diseas
cancer
patient
probabl
underestim
caus
fever
wherea
cancer
patient
would
experi
selflimit
vzvsuscept
patient
expos
chickenpox
receiv
prompt
administr
specif
immunoglobulin
drug
use
recent
year
antifung
prophylaxi
acut
leukemia
patient
fluconazol
activ
yeast
mold
posaconazol
moldact
prophylaxi
metaanalys
show
use
fluconazol
effect
prevent
fungal
infect
allogen
hsct
acut
myeloid
leukemia
suggest
possibl
benefit
popul
incid
invas
fungal
diseas
higher
fluconazol
reduc
incid
candida
infect
albican
nonalbican
obvious
diminish
risk
aspergillosi
recent
year
studi
oral
posaconazol
adult
receiv
multipl
cycl
chemotherapi
acut
myeloid
leukemia
myelodysplast
syndrom
show
statist
signific
advantag
term
mortal
absolut
reduct
rel
risk
invas
mycosi
primari
end
point
signific
reduct
also
cumul
risk
infect
compar
standard
prophylaxi
fluconazol
itraconazol
fact
differ
mortal
confirm
multivari
analysi
includ
baselin
timedepend
factor
potenti
abl
affect
surviv
limit
substanti
certainti
effect
posaconazol
surviv
benefit
given
reduct
incid
fungal
infect
incid
observ
control
group
number
need
prevent
one
provenprob
invas
mycosi
number
need
prevent
one
fungal
infectionrel
death
howev
lower
infect
rate
lower
mycosisrel
mortal
number
need
prevent
one
infect
one
death
would
higher
observ
underlin
need
everi
center
obtain
accur
inform
local
epidemiolog
invas
mycosi
therefor
tailor
result
clinic
trial
local
situat
recent
posaconazol
avail
oral
solut
absorpt
highli
variabl
depend
heavili
ingest
fatti
meal
subdivid
daili
dose
three
four
time
day
moreov
gi
side
effect
unusu
although
administr
nasogastr
tube
patient
swallow
associ
reduct
plasma
level
whether
need
therapeut
drug
monitor
posaconazol
still
controversi
recent
introduct
two
new
formul
posaconazol
ie
intraven
oral
capsul
absorpt
influenc
gastric
ph
might
resolv
problem
bioavail
oral
solut
note
posaconazol
also
effect
reduc
incid
invas
fungal
infect
allogen
hsct
recipi
graftversushost
diseas
similarli
voriconazol
anoth
moldact
azol
also
studi
set
allogen
hsct
includ
neutropen
preengraft
phase
first
studi
primari
end
point
surviv
met
voriconazol
prophylaxi
reduc
incid
invas
aspergillosi
although
statist
signific
way
efficaci
evid
among
patient
undergo
transplant
acut
myeloid
leukemia
underli
diseas
second
studi
voriconazol
superior
itraconazol
composit
end
point
main
driver
success
better
toler
efficaci
unfortun
design
voriconazol
studi
suboptim
case
lowand
highrisk
patient
includ
consequ
dilut
possibl
prophylact
effect
issu
relat
therapeut
drug
monitor
also
relev
voriconazol
case
caus
problem
oral
absorpt
result
complex
variabl
metabol
addit
triazol
especi
voriconazol
known
caus
complex
drug
interact
drug
metabol
via
cytochrom
system
risk
reduc
efficaci
treatment
increas
incid
sever
advers
event
final
prophylaxi
nebul
liposom
amphotericin
b
plu
system
fluconazol
compar
fluconazol
demonstr
effect
reduc
provenprob
ifd
repeat
period
risk
chemotherapi
acut
leukemia
adult
reduct
ifd
event
recent
system
antifung
prophylaxi
liposom
amphotericin
b
mgkg
twice
weekli
found
feasibl
safe
highrisk
pediatr
cancer
children
compar
histor
control
group
patient
histori
invas
mycosi
high
risk
reactiv
undergo
chemotherapi
recurr
unexplain
fever
document
bacteri
infect
signific
increas
rate
fluoroquinolon
resist
found
although
studi
design
evalu
impact
resist
rate
case
mani
metaanalys
import
limit
conclus
poor
qualiti
studi
includ
fact
mani
perform
decad
ago
situat
term
bacteri
epidemiolog
resist
pattern
complet
differ
soon
metaanalysi
perform
gruppo
italiano
malatti
ematologich
malign
dell
adulto
gimema
publish
random
clinic
trial
consecut
patient
acut
leukemia
lymphoma
patient
solid
tumor
confirm
valu
quinolon
prophylaxi
reduc
number
bacteri
infect
differ
surviv
statist
signific
although
trend
favor
prophylaxi
observ
proport
resist
strain
chang
time
compar
two
studi
perform
group
differ
year
author
conclud
pressur
exert
use
fluoroquinolon
prophylaxi
might
counterbalanc
decreas
need
use
empir
antibacteri
therapi
thu
limit
risk
emerg
resist
drug
use
empir
therapi
data
encompass
new
metaanalysi
publish
includ
trial
involv
patient
conduct
result
confirm
antibiot
prophylaxi
significantli
reduc
risk
death
caus
risk
infectionrel
death
compar
placebo
intervent
estim
number
need
treat
nnt
prevent
one
death
allcaus
mortal
infectionrel
mortal
prophylaxi
also
significantli
reduc
occurr
fever
clinic
microbiolog
document
infect
question
regard
antibacteri
resist
select
answer
fact
data
pivot
topic
avail
six
trial
patient
final
must
stress
studi
evalu
effect
repeat
cycl
prophylaxi
administ
whole
cours
antineoplast
chemotherapi
aforement
data
consider
chemoprophylaxi
valid
patient
hematolog
malign
undergo
hsct
popul
repres
vast
major
patient
enrol
clinic
trial
issu
prophylaxi
also
address
lowrisk
patient
undergo
standard
chemotherapi
solid
tumor
advantag
minor
end
point
differ
incid
sever
infect
infectionrel
overal
mortal
consequ
mani
guidelin
recommend
prophylact
administr
fluoroquinolon
expect
durat
postchemotherapi
neutropenia
longer
day
unfortun
alreadi
mention
quinolon
resist
like
relat
larg
sometim
improp
use
drug
human
veterinari
medicin
increas
worldwid
importantli
quinolon
resist
may
lead
emerg
bacteria
display
crossresist
aminoglycosid
reason
intern
guidelin
recommend
implement
systemat
surveil
monitor
rate
quinolon
resist
among
gramneg
pathogen
author
recommend
fluoroquinolon
prophylaxi
abandon
probabl
ineffectivewhen
resist
rate
among
escherichia
coli
greater
unfortun
exactli
case
mani
hematolog
center
throughout
world
conclus
use
quinolon
antibacteri
prophylaxi
febril
neutropenia
advantag
disadvantag
may
still
repres
valid
option
center
low
incid
resist
suscept
trend
close
monitor
center
high
rate
resist
quinolon
prophylaxi
make
littl
sens
invas
mycos
sever
complic
antineoplast
chemotherapi
especi
patient
acut
leukemia
role
increas
recent
year
although
fungal
infect
usual
repres
infect
see
tabl
associ
mortal
high
therefor
prevent
invas
fungal
infect
alway
consid
desir
approach
two
main
antivaricellazost
viru
vzv
immunoglobulin
within
hour
exposur
repres
recommend
prophylact
approach
although
protect
guarante
antivzv
immunoglobulin
avail
case
delay
notif
risk
contact
valacyclovir
g
three
time
daili
adult
weigh
kg
option
although
efficaci
establish
prophylact
chemotherapi
start
third
day
contact
continu
day
exposur
antivzv
immunoglobulin
varizig
given
valacyclovir
continu
day
exposur
incub
period
significantli
prolong
case
passiv
immun
lamivudin
mgdaili
start
week
chemotherapi
possibl
continu
least
month
end
chemotherapi
offer
patient
inact
hbv
infect
hbsag
posit
hbv
dna
neg
low
level
addit
prophylaxi
hbv
reactiv
could
use
patient
resolv
hbv
infect
hbsag
neg
hbcab
posit
case
allogen
hsct
rituximab
administr
latent
tuberculosi
tb
may
reactiv
immunosuppress
antineoplast
chemotherapi
although
specif
studi
cancer
patient
perform
data
immunocompromis
patient
mostli
hivposit
show
daili
isoniazid
monotherapi
month
altern
rifapentin
isoniazid
weekli
month
effect
treat
latent
tb
infect
colonystimul
factor
use
aim
facilit
doseintens
treatment
decreas
treatmentrel
complic
prevent
develop
neutropenia
reduc
durat
solid
tumor
studi
use
prophylact
granulocyt
colonystimul
factor
gcsf
consist
demonstr
decreas
length
sever
neutropenia
decreas
incid
febril
neutropenia
contrari
patient
hematolog
malign
gcsf
significantli
reduc
durat
sever
neutropenia
without
signific
reduct
febril
complic
durat
hospit
surviv
two
studi
compar
antibiot
gcsf
prevent
febril
neutropenia
assess
togeth
metaanalysi
nonstatist
signific
differ
favor
antibiot
demonstr
sever
guidelin
consist
recommend
prophylact
use
gcsf
adult
cancer
patient
receiv
chemotherapi
regimen
associ
risk
febril
neutropenia
patient
lower
risk
relev
comorbid
older
age
advanc
underli
diseas
final
patient
solid
tumor
experienc
neutropenia
fever
previou
cycl
may
benefit
prophylact
administr
gcsf
subsequ
cycl
chemotherapi
children
studi
perform
patient
solid
tumor
neutropen
period
show
risk
fever
repeat
episod
neutropenia
influenc
use
gcsf
base
experi
patient
primari
immunodefici
syndrom
administr
immunoglobulin
recommend
patient
secondari
iatrogen
immunoglobulin
defici
patient
acut
chronic
lymphocyt
leukemia
nonhodgkin
lymphoma
receiv
rituximab
keep
immunoglobulin
g
level
greater
mgdl
associ
reduct
infecti
episod
provid
treatment
could
given
least
month
treatment
reduc
bacteri
infect
effect
viral
fungal
invas
aspergillosi
hsct
associ
less
month
antifung
therapi
persist
radiolog
abnorm
treatment
therefor
secondari
antifung
prophylaxi
recommend
hsct
highintens
chemotherapi
patient
previou
ifd
drug
secondari
prophylaxi
chosen
accord
etiolog
primari
infect
local
drug
avail
formul
risk
interact
therapi
especi
treatment
underli
diseas
recent
year
p
jirovecii
pneumonia
describ
increas
frequenc
nonhuman
immunodefici
viru
hiv
patient
risk
particularli
high
patient
acut
especi
lymphoblast
leukemia
nonhodgkin
lymphoma
macroglobulinemia
multipl
myeloma
chronic
lymphocyt
leukemia
treat
standard
chemotherapi
undergo
autolog
transplant
patient
risk
complic
central
nervou
system
solid
tumor
correl
prolong
use
highdos
steroid
alkyl
agent
temozolomid
receiv
bendamustin
breast
cancer
sever
drug
affect
cellmedi
immun
also
associ
risk
p
jirovecii
pneumonia
includ
fludarabin
arac
cytarabin
methotrex
dactinomycin
bleomycin
lasparaginas
addit
pneumocystosi
associ
administr
alemtuzumab
caus
profound
deplet
lymphocyt
rare
rituximab
one
case
also
multikinas
inhibitor
desatinib
howev
clear
whether
biolog
drug
may
sole
respons
increas
infect
risk
whether
concomit
previou
treatment
purin
analogu
alkyl
agent
steroid
contribut
significantli
risk
pneumocystosi
durat
risk
treatment
discontinu
known
exact
dose
durat
steroid
therapi
suffici
predispos
infect
absolut
lymphocyt
count
less
proport
less
similar
agerel
valu
children
suggest
indic
prophylaxi
least
bone
marrow
transplant
efficaci
toler
mg
tmpsmx
given
three
seven
time
week
compar
one
doublestrength
tablet
three
time
weekli
remain
best
prophylact
option
provid
patient
strictli
compliant
prescript
drug
daili
oral
dapson
atovaquon
monthli
aerosol
pentamidin
demonstr
efficaci
altern
option
patient
toler
tmpsmx
see
chapter
exclus
acyclovir
valacyclovir
prevent
herp
simplex
viru
reactiv
hsvposit
patient
therapi
acut
leukemia
recipi
hsct
primari
antivir
chemoprophylaxi
current
recommend
patient
solid
tumor
lymphoma
acut
chronic
leukemia
howev
new
drug
pose
new
challeng
reason
patient
includ
alemtuzumab
clinic
trial
receiv
antivir
prophylaxi
acyclovir
mg
three
time
day
famciclovir
mg
two
time
day
valacyclovir
mg
two
time
day
least
month
complet
therapi
studi
recommend
dose
acyclovir
prophylaxi
hsv
adult
weigh
kg
approxim
mgday
oral
given
mg
two
five
time
daili
mg
twice
daili
mgm
intraven
valacyclovir
mg
oral
two
time
daili
postul
never
proven
acyclovir
prophylaxi
reduc
sever
oral
stomat
may
also
reduc
incid
bacteri
infect
origin
oral
flora
regard
cmv
routin
prophylaxi
recommend
although
regular
screen
polymeras
chain
reaction
antigen
month
end
treatment
could
benefici
patient
high
risk
cmv
infect
varicella
may
sever
clinic
cours
patient
receiv
antineoplast
chemotherapi
thu
intraven
administr
influenza
season
well
patient
receiv
intens
chemotherapi
pneumococc
vaccin
import
immunocompromis
patient
although
respons
vaccin
may
suboptim
vaccin
adequ
precaut
case
liveattenu
vaccin
also
recommend
transmiss
diseas
varicella
case
noteworthi
observ
small
studi
major
difficulti
implement
varicella
vaccin
program
target
neg
household
contact
immunocompromis
children
attribut
attitud
pediatr
oncologist
parent
refus
fear
advers
event
vaccin
patient
vzv
vaccin
part
gener
vaccin
program
fever
neutropenia
alway
consid
medic
emerg
alway
regard
caus
infect
unless
proven
otherwis
febril
episod
cours
neutropenia
classifi
accord
presenc
absenc
microbiolog
clinic
document
infect
basi
febril
complic
neutropen
cancer
patient
classifi
microbiolog
document
infect
mdi
bacteremia
isol
signific
pathogen
one
blood
cultur
mdi
without
bacteremia
isol
signific
pathogen
welldefin
site
infect
urin
respiratori
secret
obtain
steril
procedur
fluid
collect
clinic
document
infect
presenc
clinic
pictur
clearli
object
infecti
natur
without
microbiolog
proof
sepsi
mening
pneumonia
neutropen
enterocol
unexplain
fever
fever
unknown
origin
clinic
microbiolog
proof
lack
clinic
cours
mere
compat
infect
purpos
start
empir
antibiot
therapi
fever
usual
defin
axillari
temperatur
greater
c
three
differ
time
within
period
temperatur
greater
c
singl
measur
develop
fever
sign
infect
without
fever
see
definit
system
inflammatori
respons
syndrom
chapter
neutropen
cancer
patient
must
alway
rais
suspicion
infect
result
prompt
diagnost
therapeut
intervent
reliabl
empir
therapi
clearli
demonstr
empir
antibiot
therapi
certainli
contribut
substanti
impress
reduct
mortal
infecti
complic
observ
last
decad
pure
epidemiolog
studi
includ
patient
elig
enter
clinic
trial
show
slightli
higher
still
accept
consid
increas
intens
chemotherapeut
regimen
mortal
rate
gramposit
gramneg
polymicrobi
bacteremia
unfortun
recent
data
show
increas
proport
infect
caus
resist
pathogen
esblproduc
enterobacteriacea
carbapenemresist
p
aeruginosa
k
pneumonia
vre
rais
mortal
neutropen
patient
inde
era
bacteri
resist
limit
number
new
antibiot
avail
especi
gramneg
rod
infecti
complic
might
start
compromis
success
cancer
treatment
well
known
past
cancer
patient
therefor
suitabl
home
care
oral
therapi
case
fever
wherea
other
requir
prompt
hospit
differ
among
cancer
patient
even
evid
current
bacteri
epidemiolog
pattern
resist
may
vari
patient
patient
case
individu
colon
resist
pathogen
center
center
case
environment
colon
countri
countri
differ
endem
resist
strain
therefor
patient
risk
sever
infect
complic
clinic
cours
infect
caus
resist
pathogen
evalu
individu
treatment
chosen
accordingli
figur
summar
possibl
initi
approach
patient
febril
neutropenia
diseas
defin
monitor
schedul
regard
often
immun
globulin
level
check
patient
chemotherapyinduc
cytopenia
clear
whether
stay
home
hospit
may
impact
develop
chemotherapyrel
complic
hospit
keep
patient
revers
isol
repres
import
tool
reduc
colon
pathogen
practic
guidelin
prevent
diffus
infecti
diseas
health
care
facil
publish
implement
ward
cancer
patient
admit
aspergillosi
mold
infect
acquir
via
respiratori
rout
use
higheffici
particul
air
filter
room
ward
leukem
transplant
patient
hospit
recommend
use
mask
adequ
filtrat
power
freeflow
pressur
could
reduc
aspergillu
colon
infect
patient
move
protect
environ
approach
demonstr
effect
togeth
physic
barrier
build
renov
addit
person
mask
could
also
prevent
diffus
respiratori
diseas
influenza
respiratori
syncyti
viru
infect
use
laminar
airflow
room
deem
necessari
impact
substanti
rate
infect
contrari
impact
neg
patient
qualiti
life
possibl
health
provid
care
properli
lowbacterialcount
diet
seem
offer
benefit
compar
normal
diet
howev
precaut
recommend
avoid
unpasteur
milk
unpasteur
mold
chees
product
raw
undercook
meat
fish
tofu
egg
unpeel
fruit
salad
unless
properli
wash
home
listeria
colon
infect
describ
associ
dairi
product
wherea
raw
veget
sprout
associ
outbreak
e
coli
salmonella
infect
although
probiot
food
live
yeast
cultur
advertis
use
reduc
risk
antibioticassoci
diarrhea
bloodstream
infect
probiot
administr
report
cancer
patient
especi
less
intens
treatment
may
seek
inform
safeti
travel
recreat
activ
although
data
exist
quantifi
risk
travel
recreat
activ
consider
made
first
assess
underli
condit
made
particular
attent
stabil
clinic
condit
patient
potenti
need
rapid
access
health
care
facil
case
remot
destin
cruis
recommend
addit
evalu
ongo
treatment
might
constitut
contraind
diseaseprevent
measur
recommend
propos
destin
vaccin
antimalaria
prophylaxi
necessari
immunocompromis
host
liveattenu
vaccin
yellow
fever
salmonella
typhi
might
contraind
wherea
effect
vaccin
hepat
might
reduc
cancer
patient
advis
part
pet
although
precaut
necessari
exampl
differ
household
member
assign
scoop
cat
litter
potenti
toxoplasma
cyst
exposur
aquarium
touch
maintain
patient
water
fish
tank
may
contamin
atyp
mycobacteria
wherea
salmonella
acquir
directli
reptil
fomit
thu
patient
avoid
contact
reptil
food
aquarium
final
larg
pet
bird
avoid
may
transmit
chlamydia
psittaci
gener
potenti
benefit
recommend
safeti
food
pet
care
travel
lifestyl
measur
weigh
unclear
valu
recommend
potenti
neg
impact
patient
nutrit
intak
qualiti
life
use
inactiv
vaccin
demonstr
safe
could
effect
especi
nonaggress
treatment
although
poor
immunolog
respons
may
occur
safeti
concern
influenza
vaccin
strongli
recommend
household
contact
patient
earli
even
treat
outpati
home
mandatori
condit
home
outpati
treatment
febril
neutropenia
includ
presenc
reliabl
caregiv
home
stabl
intraven
access
hospit
proxim
adequ
transport
necessari
facil
telephon
run
water
heat
refriger
antibiot
choic
oral
therapi
absenc
risk
factor
resist
pathogen
includ
ciprofloxacinamoxicillinclavulan
combin
moxifloxacin
monotherapi
intraven
antibiot
ceftriaxon
plu
amikacin
daili
neutropen
import
chang
natur
histori
infect
cancer
patient
increas
number
patient
solid
tumor
treat
highdos
chemotherapi
therefor
develop
neutropenia
fever
howev
patient
solid
tumor
rare
receiv
regimen
make
neutropen
day
neutropenia
rare
sever
case
patient
clinic
stabil
within
hour
appear
fever
without
fever
within
day
accord
observ
empir
therapi
febril
neutropenia
cancer
patient
everi
situat
everi
patient
modul
accord
individu
risk
factor
basi
concept
sever
studi
perform
aim
identifi
priori
scientif
way
empir
patient
popul
low
risk
sever
infect
multin
associ
support
care
cancer
mascc
score
shown
suitabl
identifi
patient
low
probabl
complic
febril
neutropenia
tabl
riskindex
score
greater
identifi
lowrisk
patient
posit
neg
predict
valu
respect
threshold
sensit
specif
respect
misclassif
rate
studi
address
issu
identifi
patient
high
risk
although
one
might
infer
mascc
score
subject
low
index
lowrisk
patient
studi
children
evalu
risk
complic
outcom
less
success
although
six
pediatr
stratif
system
identifi
lowrisk
patient
determin
retrospect
analysi
none
could
valid
separ
data
set
thu
present
recommend
singl
lowrisk
predict
rule
made
predict
specif
outcom
children
although
local
deriv
risk
stratif
strategi
incorpor
routin
clinic
manag
lowrisk
patient
reliabl
identifi
next
logic
step
would
tri
discharg
individu
approach
adopt
hematolog
transplant
unit
institut
increas
incid
bacteremia
caus
ampicillinresist
enterococci
ciprofloxacinresist
esblproduc
gramneg
pathogen
note
result
led
chang
empir
therapi
diversifi
deescal
approach
tailor
clinic
present
meropenem
plu
vancomycin
repres
empir
therapi
patient
present
sever
sepsi
septic
shock
suspect
bacteri
pneumonia
avoid
inadequ
treatment
bacteremiafor
exampl
caus
esblposit
enterobacteriaceaeand
provid
adequ
treatment
enterococci
methicillinresist
staphylococci
vancomycin
discontinu
within
day
necessari
meropenem
chang
piperacillintazobactam
ceftazidim
suscept
pathogen
isol
colistin
andor
aminoglycosid
includ
initi
regimen
case
previou
infect
colon
mdr
gramneg
pathogen
wherea
linezolid
use
case
staphylococc
enterococc
pneumonia
less
sever
condit
ie
fever
pneumonia
stabl
hemodynam
condit
escal
approach
still
use
piperacillintazobactam
firstlin
empir
monotherapi
empir
therapi
antibiot
administ
maxim
dosag
accord
best
infus
schedul
base
pharmacokineticpharmacodynam
paramet
mani
expert
use
continu
prolong
hour
infus
way
serum
concentr
remain
substanti
higher
minim
inhibitori
concentr
mic
major
pathogen
treatment
period
although
univers
valu
administr
scheme
question
tabl
summar
major
antibiot
use
empir
target
therapi
febril
neutropenia
consider
grow
antimicrobi
resist
scarciti
new
antibiot
molecul
infect
control
antimicrobi
stewardship
implement
cancer
center
infect
control
practic
includ
surveil
contain
appropri
screen
resist
pathogen
prevent
measur
proper
hand
hygien
contact
precaut
patient
colon
infect
resist
bacteria
activ
surveil
exampl
rectal
swab
carbapenemaseproduc
k
pneumonia
vre
perform
institut
pathogen
regularli
encount
knowledg
proper
hand
hygien
techniqu
suffici
effect
prevent
pathogen
spread
supplement
regular
monitor
adher
facil
ensur
access
adequ
hand
hygien
station
sink
alcoholbas
rub
etc
contact
precaut
includ
hand
hygien
use
dispos
gown
glove
care
colon
infect
patient
fever
unknown
origin
switch
therapi
intraven
oral
eg
ciprofloxacin
cefixim
also
demonstr
safe
practic
next
section
manag
highrisk
patient
new
challeng
present
mdr
pathogen
discuss
howev
emphas
increas
resist
necessarili
affect
highrisk
patient
present
specif
set
hospit
countri
lowrisk
patient
well
specif
composit
regimen
empir
therapi
febril
neutropenia
highrisk
patient
remain
controversi
subject
chang
although
result
clinic
trial
play
pivot
role
choic
effect
regimen
factor
consid
includ
local
bacteri
epidemiolog
resist
pattern
local
antibiot
polici
antibiot
toxic
cost
recent
year
antibiot
resist
local
stewardship
polici
cost
shortag
new
antibiot
especi
gramneg
organ
dramat
complic
treatment
choic
forc
physician
diversifi
empir
regimen
base
colon
local
epidemiolog
antibiot
polici
last
least
patient
safeti
patientrel
factor
clinic
present
organ
failur
statu
underli
diseas
expect
durat
neutropenia
extrem
import
therapeut
diversif
key
time
point
manag
highrisk
neutropen
patient
fever
infect
day
patient
evalu
cultur
drawn
antibiot
therapi
start
day
result
come
back
laboratori
patient
reevalu
time
line
indic
empir
regimen
need
left
unchang
day
highlight
mandatori
reevalu
applic
discontinu
part
empir
strategi
confirm
necessari
fact
empir
antibiot
regimen
modifi
anytim
base
patient
clinic
condit
need
broader
coverag
deescal
strategi
case
sudden
deterior
microbiolog
result
escal
therapi
ie
start
rel
narrowspectrum
coverag
adjust
therapi
necessari
seem
appropri
set
resist
bacteria
infrequ
major
expert
consid
infrequ
less
speci
resist
cover
enterobacteriacea
p
aeruginosa
except
mdr
strain
monotherapi
antipseudomona
antibiot
ceftazidim
cefepim
piperacillintazobactam
probabl
repres
ration
approach
clinic
center
without
evid
resist
phenomena
carbapenem
use
secondlin
therapi
fail
patient
without
document
infect
standard
clinic
situat
combin
aminoglycosid
deem
necessari
possibl
increas
toxic
clinic
advantag
efficaci
clearli
shown
doubleblind
placebocontrol
clinic
trial
compar
piperacillintazobactam
placebo
versu
drug
amikacin
escal
approach
avoid
univers
usual
unnecessari
upfront
use
antibiot
broadest
spectrum
carbapenem
combin
aminoglycosid
glycopeptid
consequ
minim
potenti
disadvantag
select
resist
pathogen
toxic
howev
light
increas
resist
grow
concern
initi
regimen
fail
cover
pathogen
respons
infect
prognosi
worsen
significantli
deescal
therapythat
start
broad
initi
empir
regimen
carbapenem
cover
esblproduc
enterobacteriacea
resist
p
aeruginosa
without
vancomycin
mrsa
mrse
penicillinresist
gramposit
coccimay
appropri
clinic
center
high
incid
infect
caus
resist
bacteria
patient
risk
factor
resist
pathogen
tabl
use
carbapenem
vancomycin
associ
emerg
carbapenemresist
enterobacteriacea
visa
key
point
deescal
strategi
reassess
antibiot
treatment
hour
downgrad
therapi
narrowspectrum
regimen
whenev
possibl
broad
coverag
discontinu
deescal
suscept
isol
pathogen
known
andor
optim
dose
colistin
remain
establish
recent
studi
adult
report
use
iu
daili
pharmacolog
analys
support
use
load
dose
iu
follow
iu
everi
hr
see
chapter
recommend
dose
unit
state
mg
colistin
basekg
load
mg
colistin
basekgday
two
three
divid
dose
order
colistimeth
dose
per
day
would
mgkg
divid
two
three
dose
contraind
presenc
risk
factor
renal
toxic
eg
impair
renal
function
baselin
nephrotox
comed
includ
aminoglycosid
antibiot
histori
previou
toxic
therapeut
drug
monitor
might
use
assess
trough
level
rang
efficaci
patient
age
year
year
weigh
less
kg
otherwis
dose
adult
age
year
older
therapeut
drug
monitor
highli
recommend
children
metabol
voriconazol
rapidli
adult
patient
cohortingthat
feasibl
patient
place
singl
room
otherwis
placement
togeth
patient
colon
pathogen
recommend
addit
utmost
import
notifi
promptli
complet
unit
hospit
involv
patient
care
isol
pathogen
antimicrobi
stewardship
includ
follow
four
main
aspect
local
surveil
antibiot
resist
antibiot
consumpt
patient
outcom
develop
regular
updat
protocol
algorithm
diagnosi
prevent
treatment
infect
prompt
report
microbiolog
result
laboratori
allow
time
deescal
broadspectrum
empir
regimen
shorten
antibiot
therapi
optim
dose
regimen
aspect
call
multidisciplinari
approach
close
collabor
treat
oncologist
hematologist
microbiolog
laboratori
infecti
diseas
consult
servic
includ
infect
control
unit
hospit
pharmaci
durat
empir
antibiot
therapi
neutropen
patient
extens
evalu
random
clinic
trial
demonstr
significantli
effect
control
differ
base
lower
toxic
interest
metaanalysi
six
trial
empir
treatment
compar
treatment
preemptiv
therapi
confirm
empir
antifung
treatment
associ
lower
rate
diagnos
invas
fungal
diseas
gave
signific
advantag
term
overal
mortal
aim
empir
therapi
treat
earli
possibl
candidiasi
aspergillosi
howev
fluconazol
prophylaxi
becam
wide
use
reduc
incid
candida
infect
becam
evid
empir
therapi
mainli
direct
aspergillu
recent
year
awar
grown
empir
approach
result
tremend
overtreat
one
symptom
fever
encourag
develop
preemptiv
mayb
better
diagnosticdriven
approach
aim
treat
fungal
diseas
highli
suggest
although
conclus
diagnost
criteria
present
fever
diagnosticdriven
strategi
clinic
consider
fever
thorac
pain
cough
biolog
marker
eg
aspergillu
galactomannan
serum
bronchoalveolar
lavag
bal
fluid
cytolog
detect
fungal
hypha
posit
cultur
sputum
bal
fluid
imag
data
eg
chest
comput
tomographi
ct
wholevolum
scan
thinslic
reconstruct
prefer
highresolut
ct
scan
combin
togeth
obtain
highest
possibl
diagnost
likelihood
aspergillosi
consequ
start
therapi
whether
pulmonari
infiltr
enough
typic
radiolog
sign
invas
aspergillosi
requir
start
antifung
therapi
matter
debat
studi
analyz
feasibl
approach
adult
patient
first
one
conclud
diagnosticdriven
approach
feasibl
associ
less
use
antifung
therapi
without
increas
mortal
respect
histor
control
particular
interest
studi
patient
diagnos
posit
galactomannan
ct
scan
would
receiv
antifung
therapi
classic
empir
approach
afebril
first
random
noninferior
trial
compar
empir
preemptiv
approach
defin
differ
previou
studi
differ
found
primari
end
point
surviv
expect
arm
preemptiv
therapi
activ
diagnost
workup
perform
fungal
infect
arm
studi
patient
stratifi
statu
underli
diseas
lower
limit
confid
interv
differ
surviv
two
strategi
among
patient
first
remissioninduct
therapi
highest
risk
period
exactli
predefin
delta
limit
thu
lead
investig
conclud
noninferior
demonstr
subgroup
studi
compar
two
strategi
result
consist
favor
diagnosticdriven
approach
pitfal
use
diagnosticdriven
approach
first
need
wellequip
radiolog
depart
skill
radiologist
will
collabor
second
mani
clinic
center
worldwid
afford
quit
expens
antigendetect
assay
third
even
test
avail
turnaround
time
crucial
allow
time
intervent
final
demonstr
moldact
prophylaxi
might
lead
reduct
sensit
specif
galactomannan
test
therefor
lower
reliabl
remain
controversi
whether
effect
mere
result
activ
antimold
drug
prevent
aspergillosi
case
obvious
prevent
galactomannan
spread
bloodstream
therefor
detect
real
effect
test
perform
conclus
opinion
empir
diagnosticdriven
strategi
mutual
exclus
combin
two
eg
lung
ct
scan
combin
feverdriven
approach
probabl
wisest
integr
clinic
approach
mold
infect
cancer
patient
exampl
empir
antifung
therapi
could
start
clinic
suspicion
await
result
diagnost
procedur
discontinu
result
confirmatori
figur
summar
possibl
approach
patient
persist
febril
neutropenia
tabl
report
drug
indic
empir
target
antifung
therapi
drug
approv
empir
therapi
includ
liposom
amphotericin
b
caspofungin
tradit
empir
antibiot
continu
neutrophil
recoveri
avoid
infect
relaps
mortal
howev
two
prospect
random
studi
lowrisk
children
found
discontinu
antibiot
marrow
recoveri
result
death
caus
bacteri
infect
increas
rate
recurr
fever
observ
studi
perform
highrisk
patient
prolong
neutropenia
confirm
discontinu
antibiot
associ
relaps
fever
patient
without
increas
mortal
provid
antibacteri
treatment
restart
immedi
therefor
neutropen
patient
fever
unknown
origin
empir
antibiot
could
discontinu
greater
equal
day
patient
hemodynam
stabl
sinc
present
afebril
greater
equal
day
irrespect
neutrophil
count
close
clinic
observ
inpati
recommend
antibiot
promptli
restart
case
fever
recurr
also
ongo
random
clinic
trial
patient
hematolog
malign
solid
tumor
address
issu
case
microbiolog
clinic
document
infect
antibiot
treatment
usual
day
recommend
sign
symptom
infect
resolv
antibiot
discontinu
also
case
precaut
antibiot
therapi
could
stop
neutrophil
recoveri
provid
full
cycl
treatment
complet
frequent
therapeut
chang
common
cancer
patient
persist
fever
neutropenia
microbiolog
document
infect
treat
antibiot
accord
suscept
test
result
even
patient
clinic
condit
improv
spontan
antibiot
treatment
also
modifi
failur
suspect
instanc
deterior
clinic
condit
persist
posit
cultur
relaps
symptom
initi
infect
sign
symptom
infect
new
site
controversi
patient
remain
febril
absenc
evid
sign
clinic
deterior
also
absenc
microbiolog
clinic
document
infect
unexplain
fever
fever
unknown
origin
case
document
infect
caus
pathogen
suscept
vitro
initi
empir
regimen
gener
good
clinic
practic
infecti
diseas
suggest
persist
fever
necessarili
mean
failur
given
antibiot
regimen
especi
patient
otherwis
clinic
stabl
neutropen
patient
bacteremia
might
requir
day
defervesc
even
isol
pathogen
suscept
alloc
antibiot
regimen
therefor
like
patient
fever
otherwis
good
clinic
condit
best
clinic
option
watch
wait
evid
fever
suitabl
criterion
escal
antibiot
therapi
absenc
clinic
microbiolog
data
empir
antifung
therapi
consist
administ
antifung
drug
persist
febril
neutropen
cancer
patient
variabl
period
empir
antibacteri
therapi
usual
day
absenc
clinic
microbiolog
radiolog
document
fungal
infect
practic
base
autopsi
studi
show
fungal
infect
undetect
life
two
random
studi
enrol
total
less
patient
studi
doubl
blind
placebo
control
conclud
unequivoc
advantag
empir
antifung
approach
studi
statist
power
observ
result
small
nevertheless
empir
antifung
therapi
persist
febril
neutropen
patient
without
document
infect
becom
common
practic
mani
cancer
center
worldwid
numer
drug
test
indic
except
first
studi
use
persist
fever
surviv
main
end
point
almost
studi
use
composit
end
point
includ
five
criteria
defervesc
discontinu
toxic
treatment
baselin
fungal
infect
prevent
breakthrough
fungal
infect
surviv
gener
drug
itraconazol
wherea
drug
approv
specif
preemptiv
treatment
manag
specif
fungal
infect
beyond
purpos
chapter
final
new
issu
choic
antifung
treatment
case
fail
moldact
prophylaxi
warrant
consider
failur
moldact
prophylaxi
suspect
patient
develop
sign
symptom
suggest
fungal
infect
without
microbiolog
document
eg
lung
infiltr
unlik
caus
bacteri
superinfect
neg
galactomannan
appear
liverspleen
nodul
receiv
posaconazol
voriconazol
prophylaxi
four
possibl
explan
includ
patient
take
prophylaxi
lack
complianc
drug
absorb
posaconazol
metabol
fast
voriconazol
shown
inadequ
blood
level
new
fungal
infect
due
noncandidanonaspergillu
fungu
intrins
resist
azol
new
fungal
infect
due
azoleresist
candida
aspergillu
speci
first
two
case
adjust
dosag
without
chang
therapi
seem
adequ
option
wherea
third
fourth
case
shift
anoth
famili
caspofungin
candida
lipid
amphotericin
b
aspergillu
seem
possibl
option
role
indwel
cathet
caus
fever
infect
neutropen
patient
probabl
overestim
suspicion
cathet
actual
involv
rais
case
septic
shock
endocard
rapidli
progress
bacteri
infect
fever
concomit
sign
infect
cathet
site
includ
subcutan
tunnel
fever
develop
concomitantli
cathet
flush
addit
clinic
criteria
microbiolog
criteria
time
blood
cultur
turn
posit
differenti
coloni
count
peripher
catheterdrawn
blood
cultur
implement
treatment
tailor
accordingli
case
import
rememb
observ
cavitari
lesion
febril
neutropen
patient
acut
leukemia
rais
suspicion
bacteri
infect
especi
presenc
posit
blood
cultur
eg
aureu
gramneg
rod
fig
inde
fungal
lesion
neutropen
patient
usual
present
typic
halo
sign
nodular
lesion
cavitari
lesion
becom
appar
neutrophil
recoveri
febril
neutropen
patient
may
present
gi
sign
symptom
abdomin
pain
nausea
vomit
diarrhea
addit
fever
patient
initi
conserv
manag
bowel
rest
intraven
fluid
total
parenter
nutrit
broadspectrum
antibiot
antianaerob
activ
immedi
implement
case
especi
patient
receiv
aggress
treatment
acut
leukemia
fullblown
neutropen
enterocol
may
develop
high
fever
sever
abdomin
pain
sometim
hemorrhag
diarrhea
evolv
acut
abdomen
septic
shock
center
high
incid
c
difficil
infect
antibiot
treatment
direct
toward
pathogen
also
consid
initi
therapeut
approach
see
chapter
surgic
intervent
usual
indic
may
recommend
set
obstruct
perfor
persist
gi
bleed
despit
correct
thrombocytopenia
coagulopathi
clinic
deterior
granulocyt
transfus
donor
stimul
growth
factor
propos
desper
case
lifethreaten
bacteri
fungal
infect
patient
persist
neutropenia
unlik
recov
promptli
evid
clinic
efficaci
limit
case
report
small
seri
result
uniform
mani
case
report
suggest
effect
growth
factor
treatment
sever
lifethreaten
bacteri
fungal
infeccould
use
catheterrel
infect
proven
suspect
choic
antibiot
regimen
base
epidemiolog
cvcrelat
infect
everi
individu
center
pharmacokineticpharmacodynam
characterist
avail
antibiot
gener
rule
antigramposit
drug
alway
includ
initi
regimen
although
choic
necessarili
vancomycin
except
center
high
rate
methicillinresist
staphylococci
hand
center
staphylococci
high
mic
valu
vancomycin
isol
daptomycin
linezolid
might
consid
moreov
gramneg
organ
infrequ
singleag
polymicrobi
cvc
bacteremia
antigramneg
coverag
recommend
case
contrast
empir
inclus
antifung
drug
seem
appropri
consid
rel
low
incid
fungal
infect
clinic
set
caus
pathogen
identifi
treatment
tailor
accord
suscept
pattern
choic
empir
therapi
neutropen
patient
pulmonari
infiltr
base
type
infiltr
time
appear
infiltr
respect
onset
fever
epidemiolog
anamnest
data
exampl
viridan
streptococci
associ
acut
respiratori
distress
syndrom
neutropen
patient
sever
oral
mucos
like
possibl
penicillin
combin
glycopeptid
appear
logic
choic
pneumonia
evid
sinc
begin
febril
episod
bacteri
etiolog
suspect
antibiot
regimen
commonli
use
febril
neutropenia
highrisk
patient
use
obviou
consider
risk
highli
resist
pathogen
present
contrari
pneumonia
appar
occur
breakthrough
infect
patient
alreadi
receiv
broadspectrum
antibiot
fungal
etiolog
like
antifung
therapi
logic
although
resist
bacteri
pathogen
includ
legionella
pneumonia
also
possibl
interstiti
pneumonia
rel
rare
neutropenia
occur
case
cmv
influenza
viru
p
jirovecii
pneumonia
like
etiolog
appropri
diagnost
measur
complic
outcom
prolong
day
profound
l
neutropenia
age
older
year
uncontrol
primari
diseas
pneumonia
hypotens
multiorgan
failur
patient
pulmonari
aspergillosi
rapid
granulocyt
recoveri
associ
develop
sever
complic
pneumothorax
fatal
hemoptysi
tion
howev
metaanalysi
publish
suggest
lack
efficaci
systemat
widespread
use
gcsf
therapi
febril
neutropenia
case
use
gcsf
eg
filgrastim
daili
adult
children
may
option
patient
fever
neutropenia
high
risk
infectionassoci
complic
prognost
factor
